CA2959026C - Compositions and uses of amidine derivatives - Google Patents

Compositions and uses of amidine derivatives Download PDF

Info

Publication number
CA2959026C
CA2959026C CA2959026A CA2959026A CA2959026C CA 2959026 C CA2959026 C CA 2959026C CA 2959026 A CA2959026 A CA 2959026A CA 2959026 A CA2959026 A CA 2959026A CA 2959026 C CA2959026 C CA 2959026C
Authority
CA
Canada
Prior art keywords
present
vitamin
pharmaceutically acceptable
poly
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959026A
Other languages
English (en)
French (fr)
Other versions
CA2959026A1 (en
Inventor
Yarlagadda S. Babu
Vivekanand P. Kamath
Walter Gowan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of CA2959026A1 publication Critical patent/CA2959026A1/en
Application granted granted Critical
Publication of CA2959026C publication Critical patent/CA2959026C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Treating Waste Gases (AREA)
CA2959026A 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives Active CA2959026C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040836P 2014-08-22 2014-08-22
US62/040,836 2014-08-22
PCT/US2015/046578 WO2016029214A1 (en) 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives

Publications (2)

Publication Number Publication Date
CA2959026A1 CA2959026A1 (en) 2016-02-25
CA2959026C true CA2959026C (en) 2023-10-24

Family

ID=54012341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959026A Active CA2959026C (en) 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives

Country Status (8)

Country Link
US (1) US10905683B2 (https=)
EP (1) EP3182962B1 (https=)
JP (1) JP6824876B2 (https=)
AU (1) AU2015305214B2 (https=)
CA (1) CA2959026C (https=)
DK (1) DK3182962T3 (https=)
ES (1) ES2954451T3 (https=)
WO (1) WO2016029214A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN106632223B (zh) * 2016-08-24 2019-04-23 浙江美诺华药物化学有限公司 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法
CN106565442B (zh) * 2016-08-24 2019-07-16 浙江美诺华药物化学有限公司 3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛的制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
AU2017348305B2 (en) * 2016-10-31 2022-04-21 Biocryst Pharmaceuticals, Inc. Prodrugs of kallikrein inhibitors
CN106977382A (zh) * 2017-04-28 2017-07-25 山东新华制药股份有限公司 4‑（3‑氟苄氧基）苯甲醛的制备方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2022006232A2 (en) * 2020-07-01 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Drug repurposing for treatment of viral infections
MX2023009293A (es) * 2021-02-09 2023-10-06 Phebra Pty Ltd Metodo para preparar una composicion farmaceutica topica.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540979A (en) 1923-04-11 1925-06-09 Swift & Co Machine for testing jelly strength of glues, gelatins, and the like
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
CA3061802C (en) * 2011-09-08 2022-04-05 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
US20150273027A1 (en) * 2012-10-10 2015-10-01 Novo Nordisk Healthcare Ag Liquid pharmaceutical composition of factor vii polypeptide

Also Published As

Publication number Publication date
CA2959026A1 (en) 2016-02-25
DK3182962T3 (da) 2023-09-18
US20170266172A1 (en) 2017-09-21
WO2016029214A1 (en) 2016-02-25
AU2015305214B2 (en) 2020-04-23
EP3182962B1 (en) 2023-06-07
WO2016029214A9 (en) 2017-01-05
US10905683B2 (en) 2021-02-02
AU2015305214A1 (en) 2017-03-16
ES2954451T3 (es) 2023-11-22
JP2017525718A (ja) 2017-09-07
EP3182962A1 (en) 2017-06-28
JP6824876B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
CA2959026C (en) Compositions and uses of amidine derivatives
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
EP1949902B1 (en) USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
JP2019142956A (ja) Ｃｆｔｒが媒介する疾患の処置のための医薬組成物
AU2010222658B2 (en) Use of rosuvastatin lactols as medicaments
JP2001081031A (ja) 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
KR20230015934A (ko) 전립선암 치료 방법
RS20050470A (sr) LEKOVI U ČVRSTOM STANjU ZA ORALNU UPOTREBU
CA3060316A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP2020516622A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP5765738B2 (ja) ロスバスタチンおよびアトルバスタチン誘導体
WO2014013465A2 (en) Salts and hydrates of antipsychotics
Han et al. Discovery of a long-acting nanocrystal formulation of INND-2201, a new co-drug of pregabalin and palmitoylethanolamide with synergistic analgesic effects
SG193495A1 (en) Gallium complexes, pharmaceutical compositions and methods of use
HK1239546B (en) Compositions and uses of amidine derivatives
HK1239546A1 (en) Compositions and uses of amidine derivatives
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
WO2019008126A1 (en) NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
JP5738205B2 (ja) アトルバスタチンラクトールの薬物としての使用
EP3931179A1 (en) Compounds for prevention and treatment of obesity and related disorders
US20250325517A1 (en) Oral dosage forms of elraglusib
WO2026013581A1 (en) Dosage forms comprising a vav1 degrader
JPH0247461B2 (https=)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200824

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250811

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828